Codexis Inc. (NASDAQ:CDXS)’s share price fell 1.6% during mid-day trading on Thursday . The company traded as low as $4.22 and last traded at $4.33, with a volume of 90,738 shares traded. The stock had previously closed at $4.40.

A number of brokerages recently issued reports on CDXS. Zacks Investment Research upgraded shares of Codexis from a “sell” rating to a “hold” rating in a research note on Wednesday. HC Wainwright began coverage on shares of Codexis in a research note on Wednesday, June 1st. They issued a “buy” rating and a $6.00 price target on the stock.

The stock’s 50-day moving average is $4.16 and its 200-day moving average is $3.81. The company’s market cap is $175.80 million.

Codexis (NASDAQ:CDXS) last posted its earnings results on Tuesday, August 9th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.09. The company earned $16 million during the quarter, compared to analysts’ expectations of $15.10 million. During the same quarter last year, the firm earned ($0.14) EPS. Codexis’s revenue for the quarter was up 166.7% on a year-over-year basis. On average, equities analysts forecast that Codexis Inc. will post ($0.21) earnings per share for the current fiscal year.

In other Codexis news, major shareholder Ventures Fund Vii L.P. Vivo sold 80,000 shares of the firm’s stock in a transaction dated Thursday, August 4th. The stock was sold at an average price of $4.22, for a total value of $337,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Codexis, Inc is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing customers to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.